Jeanny B. Aragon-Ching, MD, FACP, explains reliable molecular markers that can help identify high-risk muscle-invasive bladder cancer patients who should receive neoadjuvant therapy.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content